(VCBeat) Jan. 29, 2021 -- Beijing-based Tu Pai Medical Technology Co., Ltd. (former name: Beijing Tu Pai Imaging Technology Co., Ltd.) successively closed Series A and the extended Series A round in the second half of 2020, with a total amount of nearly 150 million yuan. The Series A round and its extension was both led by SinoKing Capital, with participation from existing investors including Tsinghua Innovation Ventures, THF Ventures, TusStar Venture Capital, and new investor Zhongguancun Development Frontier Fund.

Tu Pai Medical was founded by a number of alumni from different majors of Tsinghua University, and was jointly incubated by Beijing Tsinghua Institute of Industrial Development and GHIC, a global healthcare industrial innovation center. Founded in October 2017, Tu Pai Medical is committed to the R&D and manufacturing of high-end ophthalmic equipment and optoelectronic devices.

Tu Pai Medical's commercial product line is based on "ultrahigh-speed swept-source OCT". Besides, Tu Pai Medical has also developed ophthalmology medical devices, all of which are about to enter the stage of registration. In the past six months, Tu Pai Medical has cooperated with a number of first-class hospitals at grade 3 in China in product and academic research, which has been highly praised by authoritative experts and scholars of ophthalmology, and is constantly creating new innovative achievements.

According to Tupai CEO Wang Yingqi, the fresh round of funding will be used to upgrade the existing GMP-compliant production line, improve process standards, continue to optimize core components, and develop new products, carry out clinical trials and get approvals.

Qingkong SinoKing Capital is a professional institution among the member enterprises of Qingkong Asset Management Group under Tsinghua Holdings focused on industrial investment and asset management. The company is backed by the advantages of Tsinghua's resources in production, learning and research, adhering to the concept of "based in technology, applied to finance" to cultivate strategic emerging industries and financial capital markets.